PAS — A teenage acne drug with lifelong consequences
Isotretinoin is prescribed to hundreds of thousands of teenagers every year for acne. For some, the physical, sexual, and psychiatric side effects become permanent.
What is PAS?
Post-Accutane Syndrome (PAS) describes a constellation of persistent side effects that continue indefinitely after stopping isotretinoin, sold under brand names Accutane and Roaccutane. It is a powerful synthetic retinoid prescribed primarily to teenagers and young adults for severe acne.
Research indicates that isotretinoin alters gene expression throughout the body. Studies suggest it affects androgen receptors, disrupts neurosteroid pathways, and may cause persistent epigenetic modifications that may not reverse when the drug is stopped. Unlike most medications, isotretinoin's effects are designed to outlast the course of treatment — but for some patients, so do the side effects.
Sexual side effects were not added to the FDA label until 2017 — a full 34 years after the first adverse event report in 1983. PAS has no MedDRA adverse-event code, no diagnostic criteria, and to date no pharmaceutical company has publicly funded research into the condition.
Persistent symptoms reported by patients
PAS affects sexual function, psychiatric health, and the body. Many patients are prescribed isotretinoin as teenagers and live with these effects for decades.
Sexual
- Sexual dysfunction
- Reduced libido
Neurological
- Depression
- Brain fog and cognitive impairment
- Emotional blunting
- Suicidal ideation
Physical
- Chronic joint pain
- Dry eyes (meibomian gland dysfunction)
- IBS and gastrointestinal issues
- Chronic fatigue
- Skin fragility
PAS by the numbers
34 years of silence
Accutane approved by FDA
Roche receives approval for isotretinoin to treat severe cystic acne. The drug is marketed under the brand name Accutane in the US.
First sexual dysfunction report
The first adverse event report of sexual dysfunction associated with isotretinoin is filed — just one year after approval.
Roche pulls Accutane from the US market
After more than 7,000 lawsuits and mounting evidence of serious psychiatric and physical harm, Roche voluntarily withdraws brand-name Accutane. Generic isotretinoin continues to be prescribed widely.
Sexual side effects added to FDA label
34 years after the first report, sexual dysfunction is finally added to the US product label. By this point, millions of patients have been prescribed the drug without this warning.
Still no MedDRA code. No pharma research.
PAS has no standardized adverse-event code, no diagnostic criteria, and to date no pharmaceutical company has publicly funded a study into persistent side effects from isotretinoin.
The least researched condition
PAS is the least studied of the three persistent drug-injury conditions. To date, there are no known pharmaceutical-funded studies. All existing research has been initiated by patients or independent academics.
Limited independent research
Unlike PFS and PSSD, which have growing bodies of peer-reviewed literature, PAS research remains sparse. Most published work consists of case reports and adverse event analyses rather than mechanistic studies.
Patient-funded efforts
The small body of existing research has been entirely patient-funded. To date, no pharmaceutical company has publicly allocated resources to investigate why isotretinoin side effects persist in some patients, despite decades of adverse event reports.
Shared mechanisms with PFS & PSSD
Emerging evidence suggests PAS shares epigenetic and neurosteroid disruption pathways with PFS and PSSD. Collaborative research across all three conditions may accelerate understanding and potential treatments.
I think I have PAS. What now?
If you recognise these symptoms, here are 5 steps you can take right now.
Help build the evidence base
Join the SIDEfxHUB patient registry to contribute anonymized data to PAS research, or connect with others in our community groups.